Genomics Market (2026-2036)

The growth of this market is mainly driven by the declining cost and increasing throughput of sequencing, the growing adoption of genomic testing in clinical diagnostics for oncology, hereditary disease, reproductive health, and infectious diseases, the expansion of national genomics programs and population-scale biobanks, and the increasing use of genomics in drug discovery and development, including target identification, biomarker discovery, and patient stratification. In addition, the commercialization of new sequencing technologies, including long-read and novel high-throughput platforms, the growth of single-cell, spatial, and multi-omic research, the application of artificial intelligence (AI) to genomic data, and the expanding use of genomics in agriculture, forensics, and environmental applications are further supporting the growth of this market.

The Genomics Market, also referred to as the genomic technologies market, genomics tools and services market, or DNA and RNA analysis market, comprises the instruments, consumables, software, and services used to analyze the structure, function, and variation of genomes for research, diagnostics, drug discovery and development, and applied applications. The market includes polymerase chain reaction (PCR) instruments and reagents, including real-time and digital PCR; sequencing platforms and consumables, including short-read and long-read NGS and Sanger sequencing; nucleic acid extraction and purification products; microarrays for genotyping and gene expression; other genomic technologies such as gene editing, transfection, and cell counting tools; bioinformatics and data analysis software; and sequencing, genotyping, and genomic testing services. The market ecosystem extends from manufacturers of genomic instruments and reagents, software developers, and service providers to academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), hospitals and diagnostic laboratories, national genomics programs, and agricultural, forensic, and environmental laboratories.

Genomics has become central to biomedical research and medicine. The cost of sequencing a human genome has fallen dramatically since the completion of the Human Genome Project, making it possible to sequence hundreds of thousands of genomes in national programs and to use genomic testing in routine clinical care. In the second quarter of 2026, Illumina, Inc. reported revenue of USD 1.16 billion, up 9.5% year over year, including sequencing consumables revenue of USD 775 million, up 5%, and sequencing instrument revenue of USD 125 million, up 31%, and raised its full-year 2026 revenue guidance to USD 4.60-4.64 billion. Sequencing, PCR, and other genomic technologies are used across basic research, translational research, clinical diagnostics, and drug development, and their combined use creates a large and diversified market.

Clinical genomics is a major driver of growth. Genomic testing is used for tumor profiling and treatment selection in oncology, hereditary cancer and cardiovascular risk testing, rare disease diagnosis, prenatal and carrier screening, pharmacogenomics, and infectious disease testing. In the second quarter of 2026, Tempus AI, Inc. reported revenue of USD 382.5 million, up 22% year over year, with oncology testing volume up 31%. At the same time, reimbursement remains an important factor; for example, Myriad Genetics reported revenue of USD 190.7 million in the second quarter of 2026, down 11% year over year, despite an 8% increase in hereditary cancer testing volume, reflecting reimbursement pressure.

National genomics programs and biobanks are generating genomic data at population scale. In June 2026, the All of Us Research Program of the NIH expanded its dataset to more than 747,000 participants, including 535,000 whole-genome sequences linked to nearly 482,000 electronic health records and more than 1.3 billion genetic variants. In the U.K., Our Future Health has recruited more than 2 million participants, Genomics England is sequencing the genomes of up to 100,000 newborns in its Generation Study, and in Europe, the 1+ Million Genomes initiative is building a cross-border genomic data infrastructure. Programs in the Middle East and Asia-Pacific are also expanding, creating demand for sequencing, genotyping, and data analysis.

The technology landscape is becoming more competitive. Illumina remains the leading provider of short-read sequencing, while Pacific Biosciences and Oxford Nanopore Technologies provide long-read sequencing, and new entrants and established companies are launching new platforms. In June 2026, F. Hoffmann-La Roche Ltd launched AXELIOS 1, a high-throughput next-generation sequencing platform based on its sequencing by expansion (SBX) technology, for research use, capable of producing whole-genome results the same day and supporting whole-genome, exome, RNA, single-cell, spatial, and methylation applications. In the first half of 2026, Oxford Nanopore Technologies plc reported revenue of approximately GBP 116.5 million, up about 10%, with clinical revenue up 35%, biopharma revenue up 25%, and applied markets revenue up 22%, while revenue declined in China and the Middle East due to stricter export controls and geopolitical tensions. Thermo Fisher Scientific, QIAGEN, Bio-Rad Laboratories, Danaher, Agilent Technologies, Revvity, and Eppendorf provide PCR, extraction, library preparation, and other genomic products, and BGI Genomics is a major provider in China.

Research funding and geopolitical factors affect the market. In February 2026, the U.S. Consolidated Appropriations Act, 2026 set the National Institutes of Health (NIH) program level at USD 47.49 billion for fiscal year 2026, an increase of 1.0% over fiscal year 2025, after the administration had proposed a cut of more than 40%. While the final appropriation reduced uncertainty, academic research spending remained cautious during the year. In addition, trade tensions between the U.S. and China have affected the genomics industry. In March 2025, China barred Illumina from exporting sequencers to the country and placed the company on its Unreliable Entity List; although China announced in November 2025 that it would lift the export ban, Illumina remained on the list, and sales outside China accounted for approximately 97% of Illumina revenue.

At the same time, the market faces challenges, including variability in research funding, reimbursement pressure on clinical genomic tests, the high cost of sequencing instruments for smaller laboratories, the complexity of managing and interpreting large genomic datasets, data privacy and ethical concerns, and trade restrictions. As a result, companies that combine competitive cost per sample, strong clinical and regulatory capabilities, integrated workflows from sample to insight, data analysis and AI capabilities, and broad geographic presence are expected to capture the largest share of growth over the forecast period.